Reviewing AIM ImmunoTech (NYSE:AIM) & Alpha Cognition (OTC:ACOGF)

AIM ImmunoTech (NYSE:AIM) and Alpha Cognition (OTC:ACOGF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for AIM ImmunoTech and Alpha Cognition, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIM ImmunoTech	0	0	2	0	3.00
Alpha Cognition	0	0	0	0	0.00

AIM ImmunoTech presently has a consensus target price of $275.00, suggesting a potential upside of 10,085.19%. Given AIM ImmunoTech’s stronger consensus rating and higher possible upside, equities research analysts plainly believe AIM ImmunoTech is more favorable than Alpha Cognition.

Volatility & Risk

AIM ImmunoTech has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500.

Earnings & Valuation

This table compares AIM ImmunoTech and Alpha Cognition”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIM ImmunoTech	$121,000.00	17.05	-$28.96 million	($24.68)	-0.11
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A

Alpha Cognition has lower revenue, but higher earnings than AIM ImmunoTech. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.0% of AIM ImmunoTech shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by company insiders. Comparatively, 31.5% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares AIM ImmunoTech and Alpha Cognition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AIM ImmunoTech	-12,594.21%	-421.73%	-147.54%
Alpha Cognition	N/A	N/A	-522.43%

Summary

Alpha Cognition beats AIM ImmunoTech on 7 of the 13 factors compared between the two stocks.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.